Abstract
Eicosanoids are biologically active lipids in both physiologic and pathophysiologic situations. These mediators rapidly generate at sites of inflammation and act through specific receptors that following the generation of a signal transduction cascade, lead to coordinated cellular responses to specific stimuli. Prostanoids, that is, prostaglandins and thromboxane A2, are active products of the cyclooxygenase pathway, while leukotrienes and lipoxins derive from the lipoxygenase pathway. In addition, a complex family of prostaglandin isomers called isoprostanes is derived as free-radical products of oxidative metabolism. While there is a wide consensus on the importance of the balance between proaggregating (thromboxane A2) and antiaggregating (prostacyclin) cyclooxygenase products in cardiovascular homeostasis, an increasing body of evidence suggests a key role also for other eicosanoids generated by lipoxygenases, epoxygenases, and nonenzymatic pathways in cardiovascular diseases. This intricate network of lipid mediators is unique considering that from a single precursor, arachidonic acid, may derive an array of bioproducts that interact within each other synergizing or, more often, behaving as functional antagonists.
| Original language | English |
|---|---|
| Pages (from-to) | 364-438 |
| Number of pages | 75 |
| Journal | Medicinal Research Reviews |
| Volume | 33 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Mar 2013 |
Fingerprint
Keywords
- Cardiovascular disease
- Eicosanoids
- Leukotrienes
- Lipoxins
- Prostanoids
ASJC Scopus subject areas
- Molecular Medicine
- Drug Discovery
- Pharmacology
Cite this
Eicosanoids and Their Drugs in Cardiovascular Diseases : Focus on Atherosclerosis and Stroke. / Capra, Valérie; Bäck, Magnus; Barbieri, Silvia S.; Camera, Marina; Tremoli, Elena; Rovati, G. Enrico.
In: Medicinal Research Reviews, Vol. 33, No. 2, 03.2013, p. 364-438.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Eicosanoids and Their Drugs in Cardiovascular Diseases
T2 - Focus on Atherosclerosis and Stroke
AU - Capra, Valérie
AU - Bäck, Magnus
AU - Barbieri, Silvia S.
AU - Camera, Marina
AU - Tremoli, Elena
AU - Rovati, G. Enrico
PY - 2013/3
Y1 - 2013/3
N2 - Eicosanoids are biologically active lipids in both physiologic and pathophysiologic situations. These mediators rapidly generate at sites of inflammation and act through specific receptors that following the generation of a signal transduction cascade, lead to coordinated cellular responses to specific stimuli. Prostanoids, that is, prostaglandins and thromboxane A2, are active products of the cyclooxygenase pathway, while leukotrienes and lipoxins derive from the lipoxygenase pathway. In addition, a complex family of prostaglandin isomers called isoprostanes is derived as free-radical products of oxidative metabolism. While there is a wide consensus on the importance of the balance between proaggregating (thromboxane A2) and antiaggregating (prostacyclin) cyclooxygenase products in cardiovascular homeostasis, an increasing body of evidence suggests a key role also for other eicosanoids generated by lipoxygenases, epoxygenases, and nonenzymatic pathways in cardiovascular diseases. This intricate network of lipid mediators is unique considering that from a single precursor, arachidonic acid, may derive an array of bioproducts that interact within each other synergizing or, more often, behaving as functional antagonists.
AB - Eicosanoids are biologically active lipids in both physiologic and pathophysiologic situations. These mediators rapidly generate at sites of inflammation and act through specific receptors that following the generation of a signal transduction cascade, lead to coordinated cellular responses to specific stimuli. Prostanoids, that is, prostaglandins and thromboxane A2, are active products of the cyclooxygenase pathway, while leukotrienes and lipoxins derive from the lipoxygenase pathway. In addition, a complex family of prostaglandin isomers called isoprostanes is derived as free-radical products of oxidative metabolism. While there is a wide consensus on the importance of the balance between proaggregating (thromboxane A2) and antiaggregating (prostacyclin) cyclooxygenase products in cardiovascular homeostasis, an increasing body of evidence suggests a key role also for other eicosanoids generated by lipoxygenases, epoxygenases, and nonenzymatic pathways in cardiovascular diseases. This intricate network of lipid mediators is unique considering that from a single precursor, arachidonic acid, may derive an array of bioproducts that interact within each other synergizing or, more often, behaving as functional antagonists.
KW - Cardiovascular disease
KW - Eicosanoids
KW - Leukotrienes
KW - Lipoxins
KW - Prostanoids
UR - http://www.scopus.com/inward/record.url?scp=84873994859&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873994859&partnerID=8YFLogxK
U2 - 10.1002/med.21251
DO - 10.1002/med.21251
M3 - Article
C2 - 22434418
AN - SCOPUS:84873994859
VL - 33
SP - 364
EP - 438
JO - Medicinal Research Reviews
JF - Medicinal Research Reviews
SN - 0198-6325
IS - 2
ER -